A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists

Between 2000 and 2005 several studies revealed that morphine is more potent and exhibits fewer side effects in beta-arrestin 2 knockout mice. These findings spurred efforts to develop opioids that signal primarily via G protein activation and do not, or only very weakly, recruit beta-arrestin. Devel...

Descripción completa

Detalles Bibliográficos

Autores principales:	Kendall L. Mores, Benjamin R. Cummins, Robert J. Cassell, Richard M. van Rijn
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Frontiers Media S.A. 2019-04-01
Colección:	Frontiers in Pharmacology
Materias:	kappa opioid receptor beta-arrestin G protein signaling bias nalfurafine diphenethylamine
Acceso en línea:	https://www.frontiersin.org/article/10.3389/fphar.2019.00407/full
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!